A study on non-small cell lung cancer demonstrated that CXCL9, a protein marker, could predict the prognosis of immunotherapy based on PD-1/PD-L1 blockade (Eltahir et al., 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.